


Based upon the foregoing, Applicants submit that the restriction requirement is improper and therefore must be withdrawn. To facilitate prosecution, however, Applicants have provisionally elected, with traverse, Group I (originally filed claims 1-4 and 6-9, and newly added claims 16-20).

Should the Examiner have any questions regarding this application, the Examiner is encouraged to contact Applicants' undersigned representative at (202) 942-5071.

As set forth in the accompanying Fee Transmittal Form filed herewith, the Commissioner is hereby requested to charge the \$80.00 fee for the presentation of one (1) independent claim in excess of three to Arnold & Porter Deposit Account No. 50-1824 referencing matter number 16517.112.

Respectfully submitted,



June E. Cohan (Reg. No. 43,741)

David R. Marsh (Reg. No. 41,408)

Date: Sept 12, 01

ARNOLD & PORTER, LLP
555 12TH Street, N.W.
Washington, D.C. 20004
(202) 942-5000 telephone
(202) 942-5999 facsimile

Marked Up Claims

2. (Once Amended) A substantially purified nucleic acid molecule [, said nucleic acid molecule]
comprising a fragment nucleic acid having from about 50 to about 100 nucleotide residues; wherein
said fragment nucleic acid exhibits complete complementarity [capable of specifically hybridizing]
to a second nucleic acid molecule having a nucleic acid sequence selected from the group consisting
of SEQ ID NO: 1 through SEQ ID NO: 69652 [or] and complements thereof.
3. (Once Amended) The substantially purified nucleic acid molecule according to claim 2,
wherein said substantially purified nucleic acid molecule comprises a microsatellite sequence.
4. (Once Amended) The substantially purified nucleic acid molecule according to claim 2,
wherein said substantially purified nucleic acid molecule comprises a region having a single
nucleotide polymorphism.